Presbia To Participate In The 2016 Baird Global Health Conference

DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a propriety optical lens implant for treating the age-related loss of near-vision, announced that Todd Cooper, President and CEO of Presbia, is scheduled to present at the Baird Annual Global Healthcare Conference being held the 7^th and 8^th of September at the Lotte New York Palace Hotel in New York City.

“We continue to see outstanding results reported by surgeons and their patients around the globe using the Presbia Microlens as the first-line surgical treatment for near-vision loss”

“We continue to see outstanding results reported by surgeons and their patients around the globe using the Presbia Microlens as the first-line surgical treatment for near-vision loss,” said Mr. Cooper. “At this conference I will discuss the excellent outcomes recently reported by Dr. Lee Jong Ho, founder of the BalGeunSeSang Eye Clinic, one of the largest and most respected refractive ophthalmology clinics in South Korea. In addition I will also discuss our strategy of focusing our commercial activities in the country.”

Mr. Cooper will be available for one-on-one meetings at the conference.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.